NCT01129310已完成2 期
A Multicentre, Open-label Phase II Study of Irinotecan, Capecitabine(Xeloda), and Oxaliplatin (IXO) as First Line Treatment in Patients With Metastatic Gastric or Gastroesophageal (GEJ) Adenocarcinoma.
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 47
- 试验地点
- 2
- 主要终点
- Overall Response Rate and dose limiting toxicity
研究概览
简要总结
The investigators hypothesize IXO chemotherapy will have an improvement in response rate and acceptable toxicity for uncurable metastatic gastric cancer compared to historical controls.
详细描述
This is a single arm, open-label, multicentre, phase II trial in which patients with metastatic gastric or GEJ adenocarcinoma will be treated with the combination of irinotecan, capecitabine, and oxaliplatin (IXO).Patients will receive the combination of irinotecan, capecitabine, and oxaliplatin at the recommended phase II dose and sequence determined by the completed phase I trial. Patients will be treated on study until disease progression, overwhelming toxicity, or consent withdrawal.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •histologically documented gastric GEJ adenocarcinoma not previously treated with palliative systemic therapy.
- •Metastatic disease based on the presence of clinically and/or radiologically documented measurable disease based on RECIST.
- •ECOG performance status of 0,1 or
- •Age ≥ 18 years
- •Life expectancy of least 3 months based on discretion of treating oncologist.
- •Adequate hematologic, hepatic, and renal function.
- •Patients who have received prior chemotherapy or radiation delivered as part of initial curative therapy (i.e. neoadjuvant or adjuvant chemotherapy administered alone and/or concurrently delivered with radiation and/or surgery) are permitted as long as that treatment was completed at least 6 months prior to study start date.
- •Patients may have received prior palliative radiotherapy (unless radiation was curative therapy to pelvis or to ≥25% of bone marrow stores) if this radiation was ≥ 4 weeks before study entry and patients must have recovered from the toxic effects of this treatment.
- •Patients may have received prior surgery if this surgery was ≥ 4 weeks before study entry and patients must have recovered from the toxic effects of this treatment.
- •Patients must have the ability to read, understand, and sign an informed consent and must be willing to comply with study treatment and follow-up.
排除标准
- •Patients who have received palliative chemotherapy for their metastatic gastric or GEJ tumor.
- •Prior treatment with > 6 cycles of traditional alkylating agent-based chemotherapy, > 2 cycles of carboplatin-based chemotherapy, prior treatment with irinotecan or oxaliplatin chemotherapy, or concurrent treatment with other experimental drugs or anti-cancer therapy.
- •Curative radiation treatment to the pelvis or radiation therapy to ≥ 25% of bone marrow stores.
- •Lack of physical integrity of the upper gastrointestinal tract, malabsorption syndrome, short gut syndrome, or history of bowel obstruction due to peritoneal metastases.
- •Previous of concurrent malignancies, excluding curatively treated in situ carcinoma of the cervix or non-melanoma skin cancer, unless at least 5 years have elapsed since last treatment and the patient is considered cured.
- •Any serious medical condition within 6 months prior to study entry such as myocardial infarction, uncontrolled congestive heart failure,unstable angina, active cardiomyopathy, unstable ventricular arrhythmia, cerebrovascular diseases, uncontrolled hypertension, uncontrolled diabetes, uncontrolled psychiatric disorder, serious infection, active peptic ulcer disease, or other medical condition that .....
- •Gilbert's disease
- •Known dihydropyrimidine dehydrogenase (DPD) deficiency.
- •Pre-existing neuropathy ≥ grade 2 from any cause.
- •Patients with unstable metastasis to the central nervous system are excluded. Patients who have treated brain metastasis and are off steroids, anticonvulsants, and have documented stability of lesions for at least 3 months may be eligible. A CT scan or MRI is NOT required to rule out brain metastases unless there is clinical suspicion of CNS involvement.
- •Pregnant of lactating women
结局指标
主要结局
Overall Response Rate and dose limiting toxicity
时间窗: 2 years
次要结局
- Progression Free Survival, overall survival, death, alterations in quality of life outcomes(2 years)
研究者
研究点 (2)
Loading locations...
相似试验
Unknown
2 期
IXO (Irinotecan, Xeloda, Oxaliplatin) in Rectal CancerRectal CancerNCT01237665Ottawa Hospital Research Institute15
已完成
2 期
Combination of CPT-11 and LoHP vs Combination of 5-FU, Leucovorin and LoHP as 1st Line Treatment in Gastric PatientsGastric CancerNCT00447967Hellenic Oncology Research Group110
已完成
2 期
Irinotecan, Carboplatin, Bevacizumab in the Treatment of Patients With Extensive Stage Small Cell Lung CancerCarcinoma, Small Cell LungNCT00294931SCRI Development Innovations, LLC50
已完成
2 期
Irinotecan Study For Cervical CancerUterine Cervical NeoplasmsNCT00136955Pfizer41
已完成
2 期
Irinotecan and Cisplatin in Treating Patients Who Are Undergoing Surgery For Locally Advanced Cancer of the Stomach or Gastroesophageal JunctionGastric AdenocarcinomaStage II Gastric CancerStage III Gastric CancerStage IV Gastric CancerNCT00062374National Cancer Institute (NCI)55